(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Islamic State group militants claim capture and execution of a Nigerian brigadier general - 2Pick Your Favored pizza beating
- 3Step by step instructions to Figure out the Natural Effect of 5G Pinnacles
- 4The German series proving subtitles can be sexy — and wildly addictive
- 5Finding the Universe of Computer generated Reality: Individual Encounters
- The 25 Most Notable Style Crossroads in History
- 5 Most Expected Film Delivery
- Best bar-b-que Style: Which One Is Your Number one?
- Scientists solve the mystery of the prehistoric 'Burtele Foot'
- Wonderful Sea shores All over the Planet
- The Way to Recuperation: Defeating Dependence
- Top 10 Smash hit Computer games of the Year
- Figure out how to Consolidate a Brain science Certificate with Social Work
- Israeli president concerned over proposed renaming of park
